Navigation Links
23andMe scientists receive more than $500,000 in National Institutes of Health funding
Date:12/4/2012

MOUNTAIN VIEW, CA December 4, 2012 23andMe has received grants totaling $573,000 from the National Institutes of Health (NIH) to support three projects that utilize 23andMe's unique web-based research platform. These include projects to better understand the genetics of allergies; to assess accuracy of new sequencing technologies in clinical applications; and to develop tools that will take advantage of the genotypic and phenotypic information in the 23andMe database to further accelerate the pace of human genetic research.

"These NIH grants recognize the ability of 23andMe's unique, web-based research platform to accelerate our understanding of human genetics," said Anne Wojcicki, co-founder and CEO of 23andMe. "23andMe is pleased to bring public funding to bear on data and research driven by the public our more than 180,000 customers."

The first of the grants will support genome wide association studies (GWAS) to discover genetic factors affecting allergic disease risk, and to assess gene environment interactions, as well as treatment responses. Asthma and allergies are extremely common, affect one in five Americans, and represent a substantial public health burden. GWAS of complex traits with both genetic and environmental contributions such as allergies - are most effective when a large cohort is used in the study. The 23andMe research cohort includes more than 25,000 individuals reporting one or more allergies, more than 8,000 reporting an asthma diagnosis and more than 5,000 reporting having eczema. In addition, the 23andMe research cohort includes more than 100,000 individuals serving as controls.

Identifying genetic associations improves understanding of disease mechanisms in the body and can inform work towards improved diagnostics and treatments of allergic conditions.

"This grant will enable 23andMe to effectively partner with leading experts and researchers in the genetics of asthma and allergies," said
'/>"/>

Contact: Jane E. Rubinstein
jrubinstein@rubenstein.com
212-843-8287
23andMe Inc.
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. 23andMe identifies 5 significant genetic associations for hypothyroidism
2. 23andMe contributes to genetic discoveries related to male pattern baldness
3. 23andMe opens its API to developers
4. 23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions
5. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
6. Queens scientists seek vaccine for Pseudomonas infection
7. Scientists produce eye structures from human blood-derived stem cells
8. American Society of Plant Biologists honors early career women scientists
9. Brandeis scientists win prestigious prize for circadian rhythms research
10. Scientists discover new method of proton transfer
11. Salk scientists open new window into how cancers override cellular growth controls
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
23andMe scientists receive more than $500,000 in National Institutes of Health funding
(Date:7/9/2015)... DUBLIN , July 07, 2015 ... has announced the addition of the "Biometrics ... and Forecasts 2015-2020" report to their offering. ... a major contributor to this growth and the ... US$5.5 billion in revenue for companies involved in ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/8/2015)... 2015 The consumer products industry for ... have products such as wearables, smart wallets & other smart ... based devices continues to rapidly grow.  Biometrics & Wearable Device ... ), Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... Inc. (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... Case Western Reserve University is part of a landmark ... which are associated with blood pressure. The 19-site meta-analysis, ... of genetic mutations are also associated with blood pressure ... Xiaofeng Zhu, PhD, is co-senior author of the paper, ...
... nearly a hundred thousand years has been found in ... The possibility that extreme life forms might exist in ... Antarctic ice sheet has fascinated scientists for decades. , ... of Antarctica continues to present major technological challenges. ...
... 62nd Annual Meeting of the American Society of Tropical ... medicine experts, will focus on research advances in the ... Africa and Asia, dengue in Central Florida, animal-borne diseases ... Researchers will present: new innovations to combat the global ...
Cached Biology News:African-American study identifies 4 genetic variants associated with blood pressure 2Life found in the sediments of an Antarctic subglacial lake for the first time 2American Society of Tropical Medicine and Hygiene 62nd Annual Meeting Nov. 13-17, Washington DC 2American Society of Tropical Medicine and Hygiene 62nd Annual Meeting Nov. 13-17, Washington DC 3
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... ... ... part of its 2015 growth plan and as a follow up to the recently announced ... Laboratories is pleased to announce that it has begun construction on a new Microbiological Laboratory. ... be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific to ...
(Date:7/29/2015)... PARIS , July 30, 2015 ... de la santé, publie ses résultats pour le ... Brandicourt commente les résultats. Visionner ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire ... - Moteurs de croissance ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... 2008, 5:00 ... EDT, FRAZER, Pa., March 31 Cephalon, Inc.,(Nasdaq: CEPH ) has scheduled its ... 1,2008., ... 4:10 p.m. EDT Q1 2008 results will be distributed by PRNewswire 4:50 ...
... year Revenue Increased 51.9% to $33.2 Million, ... Income Increased 49.3% to $12.8 Million, ... Revenue for 2008 NEW YORK and HAIKOU, Hainan, ... (OTC Bulletin Board: CPHI) which develops, manufactures, and,markets generic ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... distribution partner in Japan, has,received approval for its ... of Health, Labour and Welfare,(MHLW) for the treatment ... "We are proud to work with AnGes in ...
Cached Biology Technology:China Pharma Holdings, Inc. Announces Record 2007 Year End Results 2China Pharma Holdings, Inc. Announces Record 2007 Year End Results 3China Pharma Holdings, Inc. Announces Record 2007 Year End Results 4China Pharma Holdings, Inc. Announces Record 2007 Year End Results 5China Pharma Holdings, Inc. Announces Record 2007 Year End Results 6China Pharma Holdings, Inc. Announces Record 2007 Year End Results 7China Pharma Holdings, Inc. Announces Record 2007 Year End Results 8China Pharma Holdings, Inc. Announces Record 2007 Year End Results 9China Pharma Holdings, Inc. Announces Record 2007 Year End Results 10China Pharma Holdings, Inc. Announces Record 2007 Year End Results 11Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4
... specifically engineered for efficient drying down of ... glass cover and a post-trap with ammonia ... processing of samples in ammonium hydroxide., ... , Comes standard ...
... basic SpeedVac concentrator designed for the price-conscious ... still features a standard Teflon coated chamber ... and heat. It is designed for use ... variety of different rotors for maximum sample ...
... have active, real-time sample temperature monitoring. , ... worlds first, fully modular SpeedVac System. The ... to form an integrated unit or separated ... the first SpeedVac to have sample temperature ...
Digital display of time, vacuum and temperature , Dual vacuum control of ramping rate and ultimate level , Comes complete with RH40-12 (40 x 1.5 ml) Rotor and (2) Glass Condensation Flasks. ...
Biology Products: